Truist Securities Reiterates Buy Rating on Regeneron Pharmaceuticals, Inc. (REGN)

Market Context

Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $742.12 with a market capitalization of $77.2B. The stock has declined 5.2% over the past 52 weeks.

Analyst coverage from Truist Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Regeneron Pharmaceuticals, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Regeneron Pharmaceuticals, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 07, 2026	Morgan Stanley	Equal-Weight	N/A
Oct 07, 2026	Truist Securities	Buy	N/A
Oct 06, 2026	JP Morgan	Overweight	N/A
Oct 01, 2026	Argus Research	Buy	N/A
Oct 01, 2026	Jefferies	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View REGN Stock Page